Press Releases

-Approximately 1,100 F/MF patients now eligible for a CFTR modulator to treat the underlying cause of their disease- BOSTON --(BUSINESS WIRE)--Jun. 18, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced Health Canada has granted Marketing Authorization for TRIKAFTA ®

- Beta thalassemia: All 15 patients were transfusion independent after CTX001 infusion - - Sickle cell disease: All seven patients were free of vaso-occlusive crises after CTX001 infusion - BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.

- Treatment with VX-864 led to a statistically significant increase from baseline in plasma functional AAT levels as compared to placebo and was generally well tolerated - - Results provide proof-of-mechanism, although magnitude of treatment effect observed unlikely to translate into substantial

- With this approval approximately 1,500 children with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease for the first time - BOSTON --(BUSINESS WIRE)--Jun. 9, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today

- With this approval approximately 1,500 children with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease for the first time - BOSTON --(BUSINESS WIRE)--Jun. 9, 2021-- First paragraph, third sentence of release should read: An

BOSTON --(BUSINESS WIRE)--May 10, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 10:15 a.m. ET .

-Product revenues of $1.72 billion , a 14% increase compared to Q1 2020- - Company advancing clinical programs in six additional diseases beyond cystic fibrosis- -Multiple Phase 2 proof-of-concept study results expected in 2021 - BOSTON --(BUSINESS WIRE)--Apr.

- New indication includes people ages 12 years and older who have one copy of the F508del mutation regardless of the other mutation type - - People with gating (F/G) or residual function (F/RF) mutations now eligible for the triple combination therapy - LONDON --(BUSINESS WIRE)--Apr.

- Proof-of-concept studies of VX-548 in acute pain to initiate in the second half of the year - BOSTON --(BUSINESS WIRE)--Apr. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will advance the selective   NaV1.8 inhibitor, VX-548, into Phase 2 clinical

- Multi-year strategic research collaboration leverages Obsidian’s proprietary cytoDRiVE® platform to discover controllable genetic therapies to treat serious diseases - Vertex will pay Obsidian up to $75 million in equity, upfront payments and potential research milestones BOSTON & CAMBRIDGE,

BOSTON --(BUSINESS WIRE)--Apr. 19, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET .

- If approved, people ages 12 years and older who have one copy of the F508del mutation and a gating (F/G) or residual function (F/RF) mutation will now be eligible for triple combination therapy - LONDON --(BUSINESS WIRE)--Mar. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today

- With this approval approximately 750 people living with cystic fibrosis in Australia will be newly eligible for a CFTR modulator therapy - LONDON --(BUSINESS WIRE)--Mar. 24, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Australian Therapeutic Goods

– VX-880 is the first investigational stem cell-derived therapy utilizing fully differentiated, insulin-producing pancreatic islet cells for the treatment of type 1 diabetes – – VX-880 is the first and only pancreatic islet replacement therapy known to receive Fast Track Designation – BOSTON

BOSTON --(BUSINESS WIRE)--Feb. 24, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET . The audio portion of management's remarks will be available live through Vertex

-Full-year 2020 GAAP product revenues of $6.20 billion - -Full-year 2020 non-GAAP product revenues of $6.20 billion , a 55% increase compared to full-year 2019- -Company provides full-year 2021 product revenue guidance of $6.7 to $6.9 billion - BOSTON --(BUSINESS WIRE)--Feb.

- Vertex will initiate a Phase 1/2 clinical trial in first half of 2021 - - VX-880 is the first stem cell-derived therapy evaluating fully differentiated pancreatic islet cells for the treatment of T1D - BOSTON --(BUSINESS WIRE)--Jan. 28, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)

-FDA grants Priority Review of the application and sets a PDUFA target action date of June 8, 2021 - BOSTON --(BUSINESS WIRE)--Jan. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug

BOSTON --(BUSINESS WIRE)--Jan. 22, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .

BOSTON --(BUSINESS WIRE)--Jan. 7, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 a.m. ET ( 6:10 a.m. PT ). The audio portion of management’s remarks can be accessed